R&D at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's R&D?
- Corcept Therapeutics (CORT) reported R&D of $66.27M in Q1 2026.
- How has Corcept Therapeutics's R&D changed year-over-year?
- Corcept Therapeutics's R&D increased by 9.1% year-over-year, from $60.74M to $66.27M.
- What is the long-term trend for Corcept Therapeutics's R&D?
- Over 4 years (2021 to 2025), Corcept Therapeutics's R&D has grown at a 22.3% compound annual growth rate (CAGR), from $113.86M to $254.91M.
- What does R&D mean?
- Money spent on creating new products or improving existing ones.
- How do you interpret R&D?
- Higher spending indicates a commitment to innovation and future growth, though it reduces current profitability.
- How does R&D compare across companies?
- High R&D intensity is a hallmark of the biopharma sector compared to mature manufacturing or service industries.